Though England’s Cancer Drugs Fund has improved access to oncology medicines, it fails to address some types of long-term uncertainty. To ensure the CDF’s survival, it will need to evolve alongside the new types of treatment that are coming to the market, said Jennifer Lee, Janssen UK’s director of HEMAR (health economics market access reimbursement) and advocacy.
England could look to mechanisms used in other countries, such as treatment caps, said Lee, who was speaking at the...